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Abstract
Background: Protein O-GlcNAcylation (or O-GlcNAc-ylation) is an O-linked glycosylation involving the transfer of b-
N-acetylglucosamine to the hydroxyl group of serine or threonine residues of proteins. Growing evidences suggest
that protein O-GlcNAcylation is common and is analogous to phosphorylation in modulating broad ranges of
biological processes. However, compared to phosphorylation, the amount of protein O-GlcNAcylation data is
relatively limited and its annotation in databases is scarce. Furthermore, a bioinformatics resource for O-
GlcNAcylation is lacking, and an O-GlcNAcylation site prediction tool is much needed.
Description: We developed a database of O-GlcNAcylated proteins and sites, dbOGAP, primarily based on
literature published since O-GlcNAcylation was first described in 1984. The database currently contains ~800
proteins with experimental O-GlcNAcylation information, of which ~61% are of humans, and 172 proteins have a
total of ~400 O-GlcNAcylation sites identified. The O-GlcNAcylated proteins are primarily nucleocytoplasmic,
including membrane- and non-membrane bounded organelle-associated proteins. The known O-GlcNAcylated
proteins exert a broad range of functions including transcriptional regulation, macromolecular complex assembly,
intracellular transport, translation, and regulation of cell growth or death. The database also contains ~365 potential
O-GlcNAcylated proteins inferred from known O-GlcNAcylated orthologs. Additional annotations, including other
protein posttranslational modifications, biological pathways and disease information are integrated into the
database. We developed an O-GlcNAcylation site prediction system, OGlcNAcScan, based on Support Vector
Machine and trained using protein sequences with known O-GlcNAcylation sites from dbOGAP. The site prediction
system achieved an area under ROC curve of 74.3% in five-fold cross-validation. The dbOGAP website was
developed to allow for performing search and query on O-GlcNAcylated proteins and associated literature, as well
as for browsing by gene names, organisms or pathways, and downloading of the database. Also available from the
website, the OGlcNAcScan tool presents a list of predicted O-GlcNAcylation sites for given protein sequences.
Conclusions: dbOGAP is the first public bioinformatics resource to allow systematic access to the O-GlcNAcylated
proteins, and related functional information and bibliography, as well as to an O-GlcNAcylation site prediction tool.
The resource will facilitate research on O-GlcNAcylation and its proteomic identification.
Background
O-GlcNAcylation, or O-GlcNAc-ylation to distinguish it
from acylation, is an O-linked glycosylation involving the
b-attachment of a single N-acetylglucosamine (GlcNAc)
to the serine (Ser)/threonine (Thr) residues catalyzed by
O-GlcNAc transferase (OGT), whose removal is cata-
l y z e db yO - G l c N A c a s e( O G A )[ 1 ] .T h et w oO - G l c N A c
cycling enzymes OGT and OGA are each encoded by a
single gene in mammalian species. Unlike N-linked or
mucin-type O-linked glycosylation, O-GlcNAcylation
occurs primarily in nucleocytoplasmic proteins [1]. Ana-
logous to phosphorylation, the modification is dynamic
and the O-GlcNAc moiety is not further extended [1]. O-
GlcNAcylation is also often reciprocal to phosphorylation
at the same or adjacent Ser/Thr residues [1-3], which led
to a “Yin-Yang” hypothesis on protein functions modu-
lated by the two post-translational modifications (PTMs)
[4] through competitively blocking each other’so c c u -
pancy at given sites. For example, reciprocal O-GlcNAcy-
lation and phosphorylation at the same Ser16 of murine
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ERb by stabilizing or destabilizing the protein, respec-
tively [5]. Similarly, O-GlcNAcylation of p53 at Ser149 is
associated with decreased phosphorylation at the adja-
cent Thr155, resulting in decreased p53 ubiquitination
and subsequent degradation, thus stabilizing p53 [6]. In
contrast to the enormous body of research on phosphor-
ylation, the amount of research on O-GlcNAcylation has
been disproportionally small due to difficulties in detect-
ing the O-GlcNAc group, partly because of its being
labile, dynamic, and substoichiometric [7]. Over 600 pro-
teins have been reported to be O-GlcNAcylated since it
was first identified in 1984 [8], many of which were iden-
tified in recent years [1-3,9-11] as a result of improved
mass spectrometry technologies. Growing evidences now
suggest that O-GlcNAcylation is very common and has
broad roles in physiology and diseases, especially through
its reciprocal interplay with phosphorylation, e.g., regula-
tion of insulin signaling, transcription, and roles in dia-
betes and neurodegenerative diseases [2].
A number of bioinformatics databases have been devel-
oped for protein post-translational modifications, includ-
ing those of general PTMs, e.g., dbPTM [12], or specific
types, e.g., databases of protein phosphorylation, e.g.,
PhosphoELM [13], PhosphoSite [14], and those of pro-
tein glycosylation [15], ubiquitination [16] and protease
cleavage [17]. By contrast, there has been no special data-
base dedicated to O-GlcNAcylated proteins and sites,
and their annotations are also scarce in protein databases,
e.g., only ~100 experimental O-GlcNAcylation sites for
35 proteins are currently annotated in UniProtKB [18].
Moreover, O-GlcNAcylation annotations have not been
included in the specialized glycosylation databases (e.g.,
GlycoBase, the Functional Glycomics Gateway) [15,19].
Because of growing interests in studying the crucial
roles of O-GlcNAcylation in cell signaling and many
other cellular processes, identifying the site motifs and
computationally predicting the O-GlcNAcylation sites
become important bioinformatics tasks to assist those
studies. Unlike N-linked glcycosylation with a consensus
motif of “Asn-X-Thr/Ser”, O-linked glycosylation,
including mucin-type O-glycosylation and O-GlcNAc
glycosylation, has not yet found well-defined sequence
motifs. The past effort in developing prediction method
for O-glycosylation has mostly focused on the mucin-
type [20-23]. To our best knowledge there has been
only one site prediction tool for O-GlcNAcylation,
YinOYang, which is an artificial neural network system
trained on sequence fragments of ~40 GlcNAcylation
sites available at the time [24]. The motif of O-GlcNA-
cylation remains poorly defined, and there is a pressing
need to develop an O-GlcNAcylation site prediction
tool based on a much greater number of experimental
O-GlcNAcylation sites available now.
Here we report the development of a database of O-
GlcNAcylated proteins and sites (dbOGAP) for all cur-
rently known O-GlcNAcylated proteins reported from
literature, and of an O-GlcNAcylation site prediction
system (OGlcNAcScan) based on nearly 400 O-GlcNA-
cylation sites. Both the database and the prediction sys-
tem are available through the dbOGAP web site, which
serves as a public bioinformatics resource to facilitate
research on O-GlcNAcylated proteins and to assist pro-
teomic identification of O-GlcNAcylation sites.
Construction and Content
1. The Database Development
The primary data source used for developing the dbO-
GAP database is literature about O-GlcNAcylated pro-
teins published since O-GlcNAcylation was first
discovered in early 1980’s [8]. Figure 1 depicts the over-
all workflow of the dbOGAP database and web site
development. About 500 original and review articles
were retrieved from PubMed (April 2010) that are
related to protein O-GlcNAcylation and/or the O-
GlcNAc cycling enzymes OGT and OGA. Abstracts and
full-length articles were used to identify experimentally
determined O-GlcNAcylated proteins and sites. The
proteins were then mapped to UniProtKB entry records
based on sequences and/or sequence identifiers (IDs)
followed by manual verification. O-GlcNAcylated pro-
teins and sites determined only from large-scale mass
spectrometry (MS) without further validation using tar-
geted MS and/or additional biochemical methods were
annotated with evidence tags (e.g., “LS: MALDI-TOF-
MS”). Orthologs of known O-GlcNAcylated proteins
with identified O-GlcNAcylation sites were populated
based on the HomoloGene groups [25] and/or BLAST
neighbors [26], where the potential O-GlcNAcylation
sites on the orthologs were inferred based on the con-
served Ser/Thr residues. The experimental or inferred
O-GlcNAcylation was attributed with literature
(PubMed ID) or inference (from orthologs), respectively.
A small number of currently annotated O-GlcNAcylated
proteins in UniProtKB were also integrated into dbO-
GAP with the source attributed. Additional protein
annotations, including other protein modifications (e.g.,
phosphorylation) and site features, Gene Ontology, path-
ways and disease information were integrated into dbO-
GAP from UniProtKB [18] or iProClass [27] databases.
2. The O-GlcNAc Site Prediction
An O-GlcNAcylation site prediction system, OGlcNAcS-
can, was developed based on annotated O-GlcNAcylation
sites in dbOGAP using the SVM
light implementation of
Support Vector Machine (SVM) [28]. A training data set
of the prediction system consists of 373 positive instances
that are experimental O-GlcNAcylation sites in 167
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tive instances that are the rest of the un-annotated Ser/
Thr sites in the same protein sequences. Given a Ser/Thr
site, n upstream and n downstream amino acids were
regarded as its sequence context and then 2n+1 amino
acids, including the O-GlcNAcylated Ser or Thr residue in
the middle, were converted into a vector of binary values
(0 or 1) using the widely-used sparse encoding method
described, for example, in Julenius et al. 2005 [21]. Note, if
the site is less than n amino acid away from the sequence
terminals, the end-of-sequence symbol is padded at the
terminal as many as needed to derive a fixed-length
sequence fragment. In this encoding method, each amino
acid type and the end-of-sequence symbol is coded with
21 binary values, e.g., 100...0 (one followed by 20 zeros) for
Ala, 010...0 for Arg, ..., and 000...1 for end-of-sequence),
and the resulting feature vector consists of 21 × (2n+1)
binary values. For different values of n,w et r a i n e dS V M
classifiers with the RBF kernel. The parameters involving
these classifiers, C and g, were optimized through 5-fold
cross-validation tests, where classifiers were trained and
tested, respectively, on a four-fifths and the remaining
one-fifth of the data set for five times. We explored differ-
ent sequence encoding methods, such as frequencies of
amino acid types [21,23] and gappy bi-grams/dimers [22],
but the orthodox sparse encoding method with n =5
yielded the best prediction performance.
3. The Database and the Web site Implementation
The dbOGAP database is implemented using the open
source relational database management system, MySQL,
with tables to store and manage the O-GlcNAcylation
protein entries, O-GlcNAcylation sites from different
sources and related literature information. The database
is deployed on RedHat Enterprise Linux operating sys-
tem (version 5.5). The Apache web server (version
2.2.15) (http://httpd.apache.org/) with the security
enhanced module ModSecurity (version 2.5.10, http://
www.modsecurity.org/), was deployed for the dbOGAP
web site. All data query and retrieval from the dbOGAP
web site is accomplished by scripts written in Perl, PHP
and Javascript.
Utility
1. The Database Contents
The current version of dbOGAP contains 1163 entries,
including 798 experimentally determined O-GlcNAcylated
proteins (Figure 2, Left, A), and 365 proteins with inferred
O-GlcNAcylation sites (total 735 sites) based on O-
GlcNAcylated orthologs (Figure 2, Left, D). About 22% of
all known O-GlcNAcylated proteins (172/798) have O-
GlcNAcylation sites identified (404 sites), among which
140 proteins also have known phosphorylation sites (1581
sites) as well as 357 O-GlcNAcylation sites (Figure 2, Left,
B, C). Interestingly, 48 of those 140 proteins have 122 Ser/
Thr sites that are potentially Yin-Yang sites to be sub-
jected to possible reciprocal regulation by O-GlcNAcyla-
tion and phosohorylation, including 42 identical sites and
74 non-identical sites that are within 4 amino acids away
from each other (Table 1). Overall, the number of cur-
rently identified O-GlcNAcylation sites is only ~11% (404/
3687) of that of phosphorylation sites on all known
Figure 1 Overall workflow of dbOGAP development.
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tally determined O-GlcNAcylated proteins, most (~61%)
are of humans, and other organisms include rat (19.7%),
mouse (8%), fruit fly (6.7%), and African frog (3.1%)
(Figure 2, Right).
Functional profiles of O-GlcNAcylated proteins
We analyzed Gene Ontology (GO) profiles of currently
known human O-GlcNAcylated proteins (~490) using
t h eD A V I Dt o o l[ 2 9 ] .W ef i r s te x a m i n e dt h em a j o r
enriched GO categories of O-GlcNAcylated proteins
annotated with GO terms at higher levels of GO hierar-
chy (covering ≥10% of the proteins) (Table 2). As shown
by the GO Cellular Components profiling, O-GlcNAcy-
lated proteins are mostly those of nucleoplasmic distri-
bution, including membrane or non-membrane bounded
organelles, cytosol, cytoskeleton, and nuclear compart-
ments. The O-GlcNAcylated proteins mainly possess
nucleotide and nucleic acid binding activities and tran-
scription regulator activities (GO Molecular Function),
and participate in transcriptional regulation, macromole-
cular complex assembly, intracellular transport, transla-
tion, regulation of cell cycle and apoptosis, and
regulation of macromolecule metabolic process (GO
Biological Processes).
We further examined the O-GlcNAcylated proteins for
enrichment of GO terms at deeper levels of the GO hier-
archy. As summarized in [Additional file 1, Supplementary
Table S1], the top enriched GO biological processes relate
to protein translation, carbohydrate (glucose) metabolism,
RNA processing/splicing, and RNA/protein transport, fol-
lowed by macromolecular complex and organelle organi-
zation, regulation of cell cycle and cell death, chromosome
organization and transcription, regulation of protein and
other small molecule metabolisms. The enriched GO
molecular functions include nucleoside, nucleotide and
nucleic acid binding, transcription factor activity, protein
binding and other molecular activities. The enriched GO
cellular components include cytosol, organelle lumen and
non-membrane-bounded organelles, nuclear compart-
ments such as nucleoplasm, nuclear pore and nucleolus,
ribosome and cytoskeleton, nuclear protein complexes
and chromatin, membrane and vesicle associated spaces,
and contractile associated proteins. Notably, although sig-
nificant proportions of known O-GlcNAcylated proteins
are associated with intracellular membranes or inner side
of plasma membrane, only a few plasma transmembrane
proteins, such as glucose transporters and notch receptor
were reported to be O-GlcNAcylated [30-32]. Therefore
O-GlcNAcylated proteins are primarily nucleocytoplasmic
and are engaged in broad biological functions.
Pathways and disease processes related to O-GlcNAcylated
proteins
We examined pathway profiles of O-GlcNAcylated
human proteins using GeneGO Pathway Maps [33]. A
wide range of cellular pathways contain significant num-
bers of proteins that are known to be subjected to O-
GlcNAcylation, including pathways involved in growth,
development and differentiation, immune and inflamma-
tory responses, cytoskeleton remodeling, and metabolic
pathways such as gluconeogenesis. A total of 141 anno-
tated GeneGO pathways are significantly enriched for
the O-GlcNAcylated human proteins (p-value < 1.0E-
03). Table 3 lists 42 pathways that are enriched at a
p-value of <1.0E-05, many of which are growth factor
Figure 2 Statistics of protein entries in dbOGAP. Left, Venn diagram showing the number of O-GlcNAcylated proteins and modification sites
in the dbOGAP database. There are a total of 1163 protein entries in the database. A - Experimental O-GlcNAcylated proteins; B - Proteins with
identified O-GlcNAcylation sites (G-sites); C - Proteins with identified phosphorylation sites (P-sites); D - Proteins with inferred O-GlcNAcylation
sites based on orthologs with known O-GlcNAcylation sites. Right, Taxonomic distributions of experimentally determined O-GlcNAcylated
proteins in dbOGAP. Numbers shown in the pie chart are percentage of proteins in given species over the total number of proteins in the
database. “Other” species include Bos taurus (3 protein entries), Gallus gallus (2), Coturnix coturnix japonica (1), Rhea americana (1), Macaca
mulatta (1) and Viruses (3).
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Page 4 of 14Table 1 O-GlcNAcylation and phosphorylation occurring at identical or adjacent (+/- 4 amino acids) serine/threonine
(S/T) sites of O-GlcNAcylated proteins
UniProt ID Gene name O-GlcNAcylation site Identical phosphorylation S/T site Adjacent phosphorylation S/T site
RRP1B_HUMAN RRP1B S731 S731 T728, S732, S735
CARF_HUMAN CDKN2AIP S348 T345
VIME_HUMAN VIM S7, T33, S34, S55 S7, T33, S34, S55 S5, S8, S9, S10, S29, T33, S34, S51, S56
SPTB2_HUMAN SPTBN1 S2324 T2328
TPR_HUMAN TPR S1676 T1677
RBP2_HUMAN RANBP2 T1399 T1399 T1396, S1400
H31_HUMAN HIST1H3A S11 S11 T12
K2C8_HUMAN KRT8 S13, S15 S13 S9, S13, T14
MYC_HUMAN MYC T58 T58 S62
NUMA1_HUMAN NUMA1 S1844 S1840, S1847
PHB_HUMAN PHB T258 S254
EMSY_HUMAN EMSY S236 S238
NU214_HUMAN NUP214 T1201, S1354 T1203, S1356
CRTC2_HUMAN CRTC2 S70, S171, S173 S70, S171 T169, S171, T177
KCC4_HUMAN CAMK4 S356 S356 S360
FOXO1_HUMAN FOXO1 T317 S319
BPTF_HUMAN BPTF T2094 S2098
HCFC1_HUMAN HCFC1 T738 T738 T737
K1C18_HUMAN KRT18 S30, S31, S49 S30, S31 S30, S31, S34, S47, S53
P121A_HUMAN POM121 T693 S697
RBM14_HUMAN RBM14 S244, S254, S256, S280 S256, S280 S256
AKT1_HUMAN AKT1 T308, S473 S473, T308
ATX2L_HUMAN ATXN2L S684 S684
SYUA_HUMAN SNCA S87 S87
IKKB_HUMAN IKBKB S733 S733
ESR1_MOUSE Esr1 S10 S10 T7
SPTB2_MOUSE Sptbn1 S2323 T2327
BSN_MOUSE Bsn S1407, S2027, S2029, T2700, T2703 S2029, S2694, T2703 T1406, S2029, T2703
SYN1_MOUSE Syn1 S518, T564 S520, S568
ABLM1_MOUSE Ablim1 S496, S499 S496, S499 S494, T495, S496, S499, S502
SKT_MOUSE Skt S357 S359, S361
DEMA_MOUSE Epb49 S285 S289
RBM14_MOUSE Rbm14 S278 S280
CEBPB_MOUSE Cebpb S180, S181 S184
SRBS1_MOUSE Sorbs1 S1199, S1200, S1201 S1201 S1201
ESR2_MOUSE Esr2 S61 S61
AKT1_MOUSE Akt1 S473 S473
NOS3_RAT Nos3 S1178 T1174, S1176
SP1_RAT Sp1 S613, T641, S642, S699, S703 S613, T641, S642, S703 T641, S642, S703
LBR_RAT Lbr S96 S99
TAU_RAT Mapt S711 S711 S707, T714, S715
KPCB_RAT Prkcb T635 T635
KPCD_RAT Prkcd T295, T348 T295 S299
KPCE_RAT Prkce S368, T710 S368, T710
KPCG_RAT Prkcg T689, S690 S687
SYN1_RAT Syn1 S516, T562 S518, S566
G3P_RAT Gapdh T227 T227
LT_SV40 SV40gp6 S111, S112 S112 S112
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Gene Ontology (GO) Terms Count* % Total P-Value
GO Biological Processes
GO:0045449~regulation of transcription 108 23.48 5.90E-04
GO:0006350~transcription 93 20.22 1.99E-04
GO:0051252~regulation of RNA metabolic process 75 16.30 6.09E-03
GO:0006355~regulation of transcription, DNA-dependent 69 15.00 3.08E-02
GO:0043933~macromolecular complex subunit organization 54 11.74 1.64E-09
GO:0065003~macromolecular complex assembly 53 11.52 4.68E-10
GO:0046907~intracellular transport 52 11.30 8.96E-10
GO:0007049~cell cycle 52 11.30 2.14E-07
GO:0006412~translation 51 11.09 3.30E-21
GO:0006396~RNA processing 51 11.09 4.00E-12
GO:0008104~protein localization 51 11.09 1.91E-05
GO:0010605~negative regulation of macromolecule metabolic process 48 10.43 1.39E-06
GO:0042981~regulation of apoptosis 48 10.43 1.60E-05
GO:0043067~regulation of programmed cell death 48 10.43 2.07E-05
GO:0010941~regulation of cell death 48 10.43 2.25E-05
GO:0045184~establishment of protein localization 47 10.22 1.11E-05
GO:0010604~positive regulation of macromolecule metabolic process 47 10.22 1.55E-04
GO Molecular Function
GO:0000166~nucleotide binding 132 28.70 2.56E-13
GO:0003677~DNA binding 101 21.96 7.11E-04
GO:0032555~purine ribonucleotide binding 92 20.00 7.02E-06
GO:0032553~ribonucleotide binding 92 20.00 7.02E-06
GO:0017076~purine nucleotide binding 92 20.00 3.91E-05
GO:0030528~transcription regulator activity 83 18.04 6.87E-07
GO:0003723~RNA binding 82 17.83 2.05E-24
GO:0001882~nucleoside binding 82 17.83 1.56E-05
GO:0005524~ATP binding 81 17.61 1.03E-06
GO:0032559~adenyl ribonucleotide binding 81 17.61 1.73E-06
GO:0030554~adenyl nucleotide binding 81 17.61 1.26E-05
GO:0001883~purine nucleoside binding 81 17.61 2.16E-05
GO:0005198~structural molecule activity 56 12.17 8.96E-12
GO:0042802~identical protein binding 51 11.09 3.27E-09
GO Cellular Component
GO:0043232~intracellular non-membrane-bounded organelle 170 36.96 6.37E-29
GO:0043228~non-membrane-bounded organelle 170 36.96 6.37E-29
GO:0005829~cytosol 141 30.65 7.16E-46
GO:0031974~membrane-enclosed lumen 131 28.48 6.60E-24
GO:0043233~organelle lumen 129 28.04 1.20E-23
GO:0070013~intracellular organelle lumen 128 27.83 5.00E-24
GO:0031981~nuclear lumen 116 25.22 2.44E-25
GO:0005856~cytoskeleton 77 16.74 2.21E-08
GO:0005654~nucleoplasm 77 16.74 2.07E-18
GO:0030529~ribonucleoprotein complex 72 15.65 3.55E-29
GO:0005730~nucleolus 55 11.96 3.09E-11
GO:0000267~cell fraction 49 10.65 2.01E-03
GO:0044430~cytoskeletal part 49 10.65 1.16E-04
* The table is sorted based on counts of proteins annotated with given GO terms in each of the major GO category. The percentage of proteins with given GO
terms over total number of human O-GlcNAcylated proteins is shown (% Total). A more detailed GO profiles are shown in [Additional file 1, Supplementary Table
S1].
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Pathways P-value Count*
Development_Role of CDK5 in neuronal development 2.68E-11 12/34
Development_Gastrin in cell growth and proliferation 3.86E-11 15/62
Immune response_Gastrin in inflammatory response 2.00E-10 15/69
Signal transduction_Activation of PKC via G-Protein coupled receptor 5.21E-10 13/52
Cytoskeleton remodeling_Cytoskeleton remodeling 9.88E-10 17/102
Glycolysis and gluconeogenesis (short map) 1.43E-09 14/67
Cytoskeleton remodeling_Neurofilaments 7.28E-09 9/25
Transcription_Role of Akt in hypoxia induced HIF1 activation 1.59E-08 9/27
Immune response_MIF - the neuroendocrine-macrophage connector 1.93E-08 11/46
Development_Prolactin receptor signaling 2.50E-08 12/58
Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling 2.72E-08 16/111
Development_Gastrin in differentiation of the gastric mucosa 3.22E-08 10/38
Development_GM-CSF signaling 4.94E-08 11/50
Development_EGFR signaling pathway 6.66E-08 12/63
Cytoskeleton remodeling_Regulation of actin cytoskeleton by Rho GTPases 7.06E-08 8/23
G-protein signaling_Proinsulin C-peptide signaling 7.62E-08 11/52
Development_Glucocorticoid receptor signaling 1.04E-07 8/24
Development_VEGF signaling and activation 1.16E-07 10/43
Cell adhesion_Histamine H1 receptor signaling in the interruption of cell barrier integrity 1.85E-07 10/45
Immune response_Inhibitory action of Lipoxins on pro-inflammatory TNF-alpha signaling 1.85E-07 10/45
Signal transduction_Calcium signaling 1.85E-07 10/45
Regulation of CFTR activity (norm and CF) 2.50E-07 11/58
Translation _Regulation of translation initiation 2.92E-07 8/27
Immune response_Histamine H1 receptor signaling in immune response 3.53E-07 10/48
Immune response_IL-2 activation and signaling pathway 4.34E-07 10/49
Transcription_P53 signaling pathway 5.48E-07 9/39
Development_Slit-Robo signaling 7.19E-07 8/30
Development_Ligand-dependent activation of the ESR1/AP-1 pathway 7.81E-07 6/14
Development_PDGF signaling via STATs and NF-kB 1.24E-06 8/32
Signal transduction_AKT signaling 1.33E-06 9/43
Development_VEGF signaling via VEGFR2 - generic cascades 2.00E-06 9/45
Development_Thrombopoietin-regulated cell processes 2.00E-06 9/45
Mucin expression in CF via IL-6, IL-17 signaling pathways 2.04E-06 8/34
Development_TGF-beta-dependent induction of EMT via RhoA, PI3K and ILK. 2.43E-06 9/46
Development_PIP3 signaling in cardiac myocytes 2.93E-06 9/47
Cytoskeleton remodeling_Keratin filaments 3.24E-06 8/36
Development_Thyroliberin signaling 3.61E-06 10/61
Development_A3 receptor signaling 4.22E-06 9/49
Transport_RAN regulation pathway 4.42E-06 6/18
Immune response_IL-7 signaling in T lymphocytes 5.01E-06 8/38
Muscle contraction_Regulation of eNOS activity in endothelial cells 5.66E-06 10/64
Immune response_IL-6 signaling pathway 7.57E-06 7/29
*Number of known O-GlcNAcylated proteins over the total number of proteins annotated in the corresponding GeneGO pathways. The table is ranked based on
the pathway enrichment P-values.
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Page 7 of 14signaling (e.g., EGFR, VEGF, TGFb, and AKT) and cyto-
kine signaling (e.g., GM-CSF, IL-2, IL6/7) pathways.
Because of the broad cellular processes and pathways
that the O-GlcNAcylated proteins are known to partici-
pate in, O-GlcNAcylation may potentially play signifi-
cant roles in many pathological conditions. Indeed, four
categories of disease conditions have been implicated to
involve O-GlcNAcylation, i.e., type II diabetes, neurode-
generative diseases, cardiovascular diseases, and cancers
[34]. For example, OGT regulates insulin signaling
through O-GlcNAcylation of several important insulin
signaling molecules, e.g., IRS-1, PI3K, PDK1, and AKT1,
leading to attenuation of insulin signaling responses in
glycogen synthesis, activation of gluconeogenic genes
and glucose transporter GLUT4 translocation, thus con-
tributing to insulin resistance in type II diabetes [1,35].
Tau protein is subject to both OGlcNAcylation and
phosphorylation, and hyperphosphorylation apparently
contributes to neurofibrillary tangle formation by tau in
Alzheimer’s disease [36]. O-GlcNAcylation represents a
key regulatory mechanism in modulating vascular reac-
tivity, such as contractile and relaxant response through
modification of proteins, e.g., NOS, sarcoplasmic reticul-
umn Ca(2+)-ATPase, PKC, MAPK and cytoskeleton and
microtubule proteins [37]. O-GlcNAcylation can med-
iate cardiac stress responses and has cardioprotective
effects through transcription-mediated regulation as well
as cardiomyocyte calcium homeostasis [38]. O-GlcNA-
cylation may have general roles in cancer through its
involvement in oncogenesis or tumor suppression by
coupling cellular metabolic status to regulation of signal
transduction, transcription, and protein degradation. For
example, reducing cellular UDP-GlcNAc level in MCF-7
cells changed the O-GlcNAcylation patterns of key pro-
teins that control cell proliferation and differentiation,
including Sp1, chaperonin TCP-1 theta, and oncogene
Ets-related protein isoform 7 [39]. Many cancer genes
or tumor suppressors are known to be O-GlcNAcylated
or to interact with OGT, such as c-Myc, AKT1, AKT2,
A T F 1 ,C B P ,F O X O 1 ,T O P 1 ,p 5 3a n dH I C 1[ 4 0 ] .I n
breast cancer cells, knockdown of OGT and the result-
ing global reduction of O-GlcNAcylation inhibited cell
proliferation and metastasis ability [41].
2. The O-GlcNAcylation Site Prediction
Figure 3 (Above) shows the graphical representation of
sequence patterns surrounding the O-GlcNAcylation
sites annotated in dbOGAP using the “Two Sample
Logo” tool [42]. Enrichment of amino acids at -3/+2
position of the modified Ser/Thr, PPV(S/T)TA, can be
observed. However, the amino acid enrichment at each
position independently is not sufficient for defining a
sequence motif for O-GlcNAcylation sites. OGlcNAcS-
can was designed to exploit sequence properties through
SVM for the site prediction. The system achieved an
area under ROC (the receiver operating characteristic)
curve (AUC) of 74.3% (Figure 3, Below)i naf i v e - f o l d
cross-validation test. AUC is a widely used performance
measure of binary classifiers. A perfect classifier yields
an AUC of 100% while random guessing yields that of
50%. Although the AUC value of OGlcNAcScan is rela-
tively low, we need to consider at least the following
two factors for its interpretation. First, the fraction of
positive instances is extremely low in this task, i.e., 373
(1.23%) of 30270 Ser/Thr sites are annotated O-GlcNA-
cylation sites in dbOGAP. Some of the past studies on
PTM site prediction reported the performance of pre-
diction systems on a balanced data set, where sampled
negative sites were used in the evaluation data set (e.g.,
the ratio of positive and negative sites were made to be
1:1 (50% positive) or 1:5 (16.7% positive)). In fact, the
relative improvement of our trained SVM classifier,
when compared to random guessing [43], can be as high
as 14-fold (i.e., the precision of the classifier can be 14
times higher than the original rate of positives sites of
1.23%). The second factor to be considered is that nega-
tive instances in the evaluation data set may include
not-yet-annotated true O-GlcNAcylation sites, which
could have lowered the performance measures. We
believe, however, sequence-based prediction of O-
GlcNAcylation sites is inherently challenging. Additional
training data through further annotation of proteins and
s i t e sa sw e l la si n c o r p o r a t i o no fo t h e rf e a t u r et y p e s ,
such as physiochemical properties of amino acids and
protein structure information, may help improve the
performance.
3. The dbOGAP Web Site
The dbOGAP web site provides two primary functional-
ities, search, query and browse of O-GlcNAcylated pro-
teins and their related annotations, and de novo
prediction of O-GlcNAcylation sites (Figure 4, #1 and
#2). The dbOGAP database can be searched based on
gene/protein names or identifiers, pathway names, or
PubMed IDs. The protein entries can also be browsed
based on gene names, organisms or pathways. The
OGlcNAcScan site prediction system allows input of a
protein sequence in FASTA format or a UniProtKB
identifier (AC or ID) for site prediction. In addition,
users can contribute their annotations to the database
based on literature or from unpublished proteomic data
on newly identified O-GlcNAcylation sites (Figure 4,
#3). All O-GlcNAcylation related literature citations are
also available for browsing (Figure 4, #4).
The O-GlcNAcylated protein entry
The dbOGAP protein entries are assigned unique IDs
(e.g., OG00001) and are mapped to the corresponding
UniProtKB IDs (1433B_HUMAN) and Accessions
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Page 8 of 14(P31946). The entry report provides detailed O-GlcNA-
cylation information and evidence attributions, including
experimental and inferred O-GlcNAcylaytion data (Fig-
ure 5). O-GlcNAcylated residues and positions, as well
as other modification sites (e.g., phosphorylation) and
site features (e.g., binding sites), can be visualized in the
context of protein sequences. The entry record also pro-
vides additional annotations such as GO, pathways (e.g.,
KEGG, PID and Reactome), protein-protein interactions
(e.g., IntAct), protein families (e.g., Pfam) and diseases
(OMIM), as well as additional protein bibliography inte-
grated from UniProt and iProClass. Hyperlinks to source
databases are provided for integrated annotations in
dbOGAP entry records.
The O-GlcNAcScan report
The OGlcNAcScan report page provides a list of pre-
dicted O-GlcNAcylation sites for a given query sequence
(Figure 6). The list can be sorted based on the
Figure 3 Sequence patterns and prediction performance of O-GlcNAcylation sites. Above, Graphical representation of sequence patterns
surrounding the O-GlcNAcylation sites as determined by Two Sample Logo. The height of the amino acid character represents the relative
frequency (enrichment or depletion) of the amino acid at any given positions relative to the O-GlcNAcylated residue (S/T at position “0”). Below,
An ROC curve of OGlcNAcScan obtained in a five-fold cross-validation test. The area under this curve (i.e., AUC) is 74.3% of the plot area. The
diagonal line indicates the ROC curve of random guessing, where the corresponding AUC value is 50%.
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Page 9 of 14prediction scores, positions of predicted sites, and the
amino acids. The predicted site of interest can be high-
lighted in the protein sequence. The threshold for dis-
play of O-GlcNAcylation sites can be adjusted to
increase or reduce the number of predictions. More
detailed explanation and interpretation of the prediction
results are provided in the online help document.
The dbOGAP database download
The dbOGAP web site provides a download page (Figure
4, linked in #1) for downloading the database in several
data files, including all O-GlcNAcylated proteins, sites
and orthologs. A full bibliography of O-GlcNAcylated
proteins can also be downloaded. The data sets for devel-
oping the OGlcNAcScan system are available to the
scientific community for further development of the site
prediction (Figure 4, #2).
Discussion
Up to now, the amount of data published on protein O-
GlcNAcylation is only a fraction of that of phosphoryla-
tion, and its biological role is much less understood. Since
2006, the identification of O-GlcNAcylated proteins and
sites has been rapidly growing due to the improved mass
spectrometry technologies and O-GlcNAc enrichment
Figure 4 The dbOGAP website home page. The website provides functionalities depicted by #1-#4: 1) search and browse the O-GlcNAcylated
proteins in the database; 2) de novo prediction of O-GlcNAcylation sites for any protein sequences; 3) user annotation of O-GlcNAcylation
information; 4) search and browse the total O-GlcNAcylation bibliography. The dbOGAP web site can be accessed at http://cbsb.lombardi.
georgetown.edu/OGAP.html.
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Page 10 of 14techniques [7-9]. The dbOGAP database provides a timely
bioinformatics resource to allow readily access by the
community to the known and potential O-GlcNAcylated
proteins and sites.
While a large number of O-GlcNAcylated proteins
and sites were identified in recent years, many were
determined based on large-scale mass spectrometry and
would need to be further validated. Although O-
GlcNAcylation has been known to occur primarily in
nucleocytoplamic proteins, the GO profiles show that
O-GlcNAcylated proteins are localized in a broad range
of intracellular compartments. Interestingly, some O-
GlcNAcylated proteins are of unusual classes, e.g., ade-
nylate kinase 2 (AK2, UniProtKB: KAD2_HUMAN) [44]
localized in the mitochondria inter-membrane space,
and alpha-1-inhibitor 3 (A1i3, UniProtKB: A1I3_RAT)
Figure 5 The dbOGAP protein entry view (shown is human AKT1). The entry report provides general protein information as well as specific
O-GlcNAcylation information in the context of other posttranslational modifications and site features. The literature evidence (PMID) for the O-
GlcNAc sites (e.g. S473 and T308) is given. Clicking on any site will display the residue in the neighboring sequence context (pointed by blue
arrow). If the O-GlcNAcylation sites are inferred from orthologs with known sites (e.g. T308 of mouse AKT1, pointed by red arrow, inferred from
human AKT1 shown in the inset), sequence alignment for the inferred sites can be displayed (lower portion of the inset). Other annotations are
also included in the entry record (below the sequence section, not shown), including gene ontology, pathway, derived from UniProtKB and
iProClass.
Wang et al. BMC Bioinformatics 2011, 12:91
http://www.biomedcentral.com/1471-2105/12/91
Page 11 of 14[45], a secreted protein. Although false positive identifi-
cation of O-GlcNAcylation is not uncommon from mass
spectrometry, it is possible that such proteins may be
indeed O-GlcNAcylated. It is known that OGT has at
least three isoforms differing in N-terminal sequences
with identical catalytic domain, the mitochondrial
(mOGT) and two nucleocytoplasmic forms (ncOGT and
sOGT) [46,47]. The mOGT form was shown associated
with the mitochondrial inner membrane [46], thus con-
sistent with the observation of O-GlcNAcylation of the
mitochondrial protein AK2. There are a total of ~11 O-
GlcNAcylated proteins in dbOGAP that are known to
be secreted or have secreted forms besides cytoplasmic
ones. It is possible that only the cytoplasmic forms of
some of these proteins are O-GlcNAcylated while the
secreted ones may not, albeit experimental validation is
needed. Thus, the types and/or sources of O-GlcNAcy-
lation identification have been assigned to protein
entries as evidence attribution to annotations in the
dbOGAP database.
The OGlcNAcScan site prediction system provides a
much needed tool for studying protein glycosylation as
well as phosphorylation. Since the site prediction is
primarily based on the protein sequence context, some
Figure 6 The O-GlcNAcylation site prediction result from OGlcNAcScan (shown is human ankyrin-1). The section at the bottom displays a
ranked list of predicted O-GlcNAcylation sites (e.g., S1162 as the top one). The rank is based on the output value of the SVM classifier, which is
converted into “Estimated Precision” and “Lift” scores (see help page linked from the top of the page for explanation). The estimated precision
score is an estimated lower-bound of the precision (e.g., the score of 0.3910 indicates that at least 39.1% of sites assigned with the similar SVM
output scores are O-GlcNAcylation sites), and the Lift score is an index of relative improvement through the classifier, which is calculated as the
estimated precision divided by a constant value corresponding to the initial rate of positive sites (i.e., ~0.0123). All displayed potential sites are
shown as red “S/T” in the sequence section (middle). Clicking on any predicted site, the residue will be highlighted in the sequence (arrow).
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Page 12 of 14secreted proteins may be erroneously predicted even
with a relatively high score, e.g., T298 in mucin 4
(UniProtKB: MUC4_HUMAN) predicted with a score
of 0.287, though it is unlikely to be O-GlcNAcylated.
In such cases, a cautionary note is given to indicate
that a protein sequence being predicted is known to
have “secreted” form(s). With the continuing growth of
O-GlcNAcylation sites data, the OGlcNAcScan tool
will be further enhanced through retraining the SVM
model, as well as by integrating physiochemical prop-
erties and structural information into the SVM predic-
tion model.
Conclusion
In conclusion, the dbOGAP database and the web site
become the first of its kind in the public domain to pro-
vide readily access to a curated and systematic collection
of protein O-GlcNAcylation information, and to a state-
of-the-art O-GlcNAcylation site prediction system,
OGlcNAcScan, to assist proteomic identification of O-
GlcNAc modification sites. Thus, the dbOGAP resource
should benefit the biological community to study the
broad roles of O-GlcNAcylation in physiology and
diseases.
Availability and Requirements
The dbOGAP database and the OGlcNAcScan system
can be publicly accessed at: http://cbsb.lombardi.george-
town.edu/OGAP.html. The database and related data
sets can be downloaded at: http://cbsb.lombardi.george-
town.edu/filedown.php.
Additional material
Additional file 1: Supplementary Table S1. Major categories of O-
GlcNAcylated proteins based on GO terms at deeper level of GO
hierarchy. This table provides GO profiles at deeper level of GO terms to
complement the major GO profiles of O-GlcNAcylated proteins in Table 2.
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